Cytiva, formerly GE Healthcare Life Sciences  

United States
  • 948


We are committed to helping researchers and pharmaceutical manufacturers bring to the market  precision medicines that target very specific populations, delivering the right therapy to the right patient at the right time.

Bioprocess: Increasing capability for cell and protein investigation, drug discovery and providing solutions to support large scale manufacturing of biopharmaceuticals

Cell and gene therapy: Tools, technology and processes to support new therapies and enable researchers and pharma companies to bring these new therapies into widespread clinical use

Genomics and cellular research: Tools and technologies used by academia, biotech, diagnostics, and pharmaceutical companies to accelerate research that brings us closer to therapies or even cures for disease


Advanced diagnostic solutions and technical support
Lyo-Stable custom stabilization service: Tour our new lab

 Press Releases

  • Our Genomics and Diagnostic Solutions (G&Ds) team introduces the Sera-Xtracta Virus/Pathogen Kit to isolate DNA/RNA viruses such as COVID-19 from a variety of sample types, including swabs and blood.

    In response to the Coronavirus pandemic, molecular diagnostic laboratories and their test developers urgently need to design, manufacture, and validate assays for these pathogenic agents. In addition to the usual challenges in developing a suitable and successful diagnostic assay, there is a shortage of kits to meet the increased demand for reagents to address the need on a global level.

    To help address this urgent need, members of our Genomics and Diagnostic Solutions (G&Ds) team have been working hard to fastrack the development and testing of a solution for the purification of DNA/RNA viruses such as COVID-19 from a variety of sample types (swabs, blood and samples in universal transport media). Testing was also conducted on our existing RNASpin Kits.

    Our R&D team, together with our Field Application Scientist and Product Manager, has developed a buffer formulation that can be used in conjunction with our SeraSil-Mag silica coated superparamagnetic beads to accelerate the development of test kits. This buffer ensures that total nucleic acid is selectively bound to the bead while impurities are efficiently removed during the quick wash steps. The buffer and SeraSil-Mag beads are packaged into the the Sera-Xtracta Virus/Pathogen Kit.

    Luke T. Daum, Ph.D., tested the Sera-Xtracta Virus/Pathogen Kit using both human and murine blood samples, and compared the results with RNASpin Kits. The tests were given high priority to ensure results could be presented without delay in the hope of finding a solution to help address the limited supply of current COVID-19 test kits. Tests which typically take months to run were completed in less than two weeks. The G&Ds team works with Dr. Daum on an ongoing basis and are hugely grateful for speed and extra hours he dedicated to delivering the test results so quickly.

    The testing methods and results are documented in an application note to provide kit developers with the reference data they need to feel confident that the kit will work to detect viruses and pathogens.

    Our custom solutions team has worked around the clock to prepare this new kit for manufacture, and are now poised to talk with kit developers about their needs for the Sera-Xtracta Virus/Pathogen Kit. The kit will be made to order initially and following with further validation over the coming weeks it will be launched as a fully stocked commercial kit under the Sera-Xtracta brand.

    To turn this project around is such a short time is truly commendable, and we would like to thank our Field Application Scientist, Product Managers as well as our R&D, Custom Solutions and Marketing teams within the Genomics and Diagnostic Solutions business for their hard work, commitment and dedication to this project.

    For further information on the Sera-Xtracta Virus/Pathogen Kit, please contact our custom services team at or speak to your modality specialist.

  • Cytiva, a global provider of technologies and services that help advance and accelerate the development and manufacture of therapeutics, launches today. Previously GE Healthcare Life Sciences, Cytiva has nearly 7,000 employees and operations in 40 countries and is part of the Danaher Corporation Life Sciences platform.

    Emmanuel Ligner, President of Cytiva, says: “Our foundation of scientific expertise, our team, and our solid customer base place Cytiva in the right position to invest, develop, and accelerate growth in the industry. Our passion for helping bring life-changing therapies to patients is unwavering, and we will continue to introduce innovative technologies to the market which improve productivity for our customers.”

    Cytiva experts and technologies enabled breakthroughs in science and medicine that have shaped today's biotechnology industry. In 2019, more than 75 percent of the biological therapies approved by the United States Food and Drug Administration relied on Cytiva’s technologies for manufacturing. Additionally, Cytiva technology has contributed in the nascent area of cell and gene therapies and has done so since the first successful pediatric trial of CAR-T therapy in 2012. This area continues to have great potential and currently, there are more than 1,000 regenerative medicine clinical trials underway globally1.

    Accelerating growth, productivity, and innovation in the sector are major strategic focus areas for the company, as global demand for personalized and advanced biological therapies is ever-increasing. Cytiva drives customer-centered innovation, from idea to commercial development stages, with facilities across Asia, Europe, and the Americas. It also has centers for customer collaboration and training to enable the development of new therapies, such as the Testa Center in Uppsala, Sweden and with the University of Technology at Sydney.

    Cytiva will also continue to pursue collaborations for research, such as the center for advanced biological innovation and manufacturing in Boston with Harvard, MIT, teaching hospitals, and industry partners Fujifilm Diosynth Biotechnologies, and Alexandria Real Estate Equities, Inc.

    Cytiva’s diverse portfolio includes well-recognized brands such as ÄKTA, Amersham, Biacore, FlexFactory, HyClone, MabSelect, Sefia, Whatman, Xcellerex and Xuri. The portfolio spans a full range of instruments, consumables, digital and enterprise solutions and services for research, process development, and complete manufacturing workflows that scale according to customers’ needs.

    1The Alliance for Regenerative Medicine Q3 2019 Quarterly Report


    About Cytiva

    Cytiva is a 3.3 billion USD global life sciences leader with nearly 7000 associates operating in 40 countries dedicated to advancing and accelerating therapeutics. As a trusted partner to customers that range in scale and scope, Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit for more.

    Media Contact:
    Dodi Axelson


  • Sera-Xtracta Cell-Free DNA Kit
    Designed to select for small-fragment cfDNA while minimizing genomic DNA contamination, Sera-Xtracta Cell-Free DNA Kit offers efficient extraction and purification of cfDNA from plasma....

  • Designed to select for small-fragment cfDNA while minimizing genomic DNA contamination, Sera-Xtracta Cell-Free DNA Kit offers efficient extraction and purification of cfDNA from plasma. High yield and sensitivity make the kit well-suited for applications such as cancer diagnosis and monitoring where sample is precious.

    Request a sample

    • Efficient recovery of small-fragment cfDNA in the size range 50-300 bp: capture more cfDNA to increase sensitivity levels.
    • Minimal co-purification of higher molecular weight genomic DNA due to active selection of smaller fragments which improves sensitivity in downstream applications.
    • Scalability: one kit to cover 0.5 mL to 4 mL input of plasma.
    • Efficient extraction: procedure can be completed in less than 120 minutes.
    • Ease of use: compatible with molecular biology techniques, including next-generation sequencing (NGS), qPCR, ddPCR, BEAMing and other amplification and genotyping applications.
  • Sera-Xtracta Genomic DNA Kit
    High yield extraction of genomic DNA from whole blood, with a simplified protocol....

  • Sera-Xtracta Genomic DNA Kit offers magnetic bead based extraction and purification of genomic DNA from whole blood. The simplified protocol minimizes the co-purification of RNA, removing the need for RNAse treatment in most applications. The kit yields genomic DNA with the high purity and quality required by today’s molecular biology techniques.

    Request a sample

    • High recovery rates: 4–8 μg from 200 μL of whole blood.
    • High purity genomic DNA: purity ratio (A260/A280) greater than 1.7.
    • Simplified protocol minimizes the co-purification of RNA removing the need for RNAse treatment in most applications.
    • Compatible with molecular biology techniques, including next generation sequencing (NGS), cloning, restriction enzyme digestion, PCR amplification and genotyping applications.
  • Sera-Mag Select
    Delivers selective binding of DNA fragments for use with next-generation sequencing (NGS) and PCR clean-up....

  • Combines the exceptional binding characteristics of Sera-Mag Carboxyl Speedbeads with an optimized binding solution in a ready-to-use formulation.

    • Use a single reagent for PCR clean-up and size selection.
    • Easily control what size DNA is retained or eliminated by adding various ratios of Sera-Mag Select to your sample. This enables NGS library and PCR fragment clean-up, as well as dual size selection of libraries.
    • Uses the same protocols as existing reagents so can be directly integrated into existing workflows with minimal disruption.
    • Sera-Mag Select delivers tight distribution in size selection for high yield recovery of specific fragment sizes.
    • Suitable for manual, high throughput, and automated workflows.
    • Sera-Mag Select should be stored in the refrigerator between 2°C to 8°C. Do not freeze. Store upright and keep bottle tightly sealed.

    The DNA size range isolated from the process can be tailored to suit the user’s end requirements by adjusting the amount of reagent that is mixed with a fixed volume of sample.

    Learn more!

  • Sera-Xtracta Virus/Pathogen Kit
    For efficient, total nucleic acid (DNA/RNA) isolation from bacteria and viruses including COVID-19....

  • Sera-Xtracta Virus/Pathogen Kit for high-throughput total nucleic acid (DNA/RNA) isolation from bacteria and viruses including Adenovirus (Type 14), Influenza A (H3N2) and COVID-19.

    • Offers the advantages of solid phase extraction (using magnetic beads) and reproducible yields.
    • Simplified protocol can be adapted for both manual and automated high-throughput processing.
    • Scalable up to 400 µL of sample.
    • Rapid extraction procedure can be completed in less than 30 minutes.
    • For use with respiratory biological matrices, blood and universal transport media to support the sensitive downstream detection of viruses and other pathogens found in low concentrations.
    • Compatible with molecular biology techniques, including quantitative polymerase chain reaction (qPCR, RT-qPCR), droplet digital PCR (ddPCR), and next-generation sequencing (NGS).

    Sera-Xtracta Virus/Pathogen Kit provides a simple and rapid method to optimize the workflow for sensitive detection system for viruses and other pathogens found in low concentrations.

    Learn more
  • SeraSil-Mag silica coated superparamagnetic beads
    Silica coated superparamagnetic beads for nucleic acid isolation deliver high purity DNA for NGS applications....

  • SeraSil-Mag silica coated superparamagnetic beads for nucleic acid isolation deliver high purity DNA extraction for highly sensitive applications where sample is scarce. These beads provide an optimal surface for nucleic acid binding with high performance and low background.

    • High magnetization (60 emu/g) and strong binding capacity giving fast magnetic response (~5 secs) and shorten time required for magnetic steps during isolation.
    • Beads come in two sizes (submicroscale diameter 700 nm and 400 nm), offering choice based on surface requirements and high binding capacity due to the small sized particles.
    • Beads are monodispersed with narrow size distribution for consistent, reproducible results.
    • Silanol hydroxyl groups on the bead surface give efficient, high purity isolation of nucleic acids.
    • Tested for microbial contamination.
    • Good buoyancy stability (low sedimentation rate): beads remain well suspended and dispersed for over 90 mins (at 1 mg/mL concentration),* providing good handling and suitability for automation. *Beads may settle faster at higher concentration.